Physician profile
Letitia Tierney
NPI 1679792493
$1,112.70
in general payments reported to CMS, 2019-2025
13 companies · $99.40 in 2025
The $99.40 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $105 · 2021: $15.93 · 2022: $98.11 · 2023: $235 · 2024: $447 · 2025: $99.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $781.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $497.30 | 2019-2024 | Vraylar, Ubrelvy, Qulipta |
| Gilead Sciences, INC. | $228.26 | 2019-2024 | Epclusa |
| Astrazeneca Pharmaceuticals LP | $160.92 | 2024-2025 | Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $48.62 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $35.05 | 2022-2023 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $27.84 | 2025 | Injectafer |
| Lundbeck LLC | $20.54 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $18.75 | 2022 | |
| Exact Sciences Corporation | $17.26 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $16.58 | 2024 | Zepbound, Mounjaro |
| Biodelivery Sciences International, INC. | $15.93 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.28 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Letitia Tierney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.